Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Magnesium and Reduced Pain Intensity

Safety in these studies
  • Overall tolerabilityReported0/35 events in intravenous magnesium group versus 0/35 in placebo group

    The evidence is very uncertain about the risk of adverse events with intravenous magnesium (0/35 events in intravenous magnesium group versus 0/35 in placebo group; 1 study, 70 participants; very low certainty).

    from: Ketamine and other NMDA receptor antagonists for chronic pain.
1 of 1 paper

  • Ketamine and other NMDA receptor antagonists for chronic pain.

    • 2025-08-18
    • Meta-Analysis · n = 2,309
    • The Cochrane database of systematic reviews 2025(8)
      • Michael C Ferraro
      • Aidan G Cashin
      • Eric J Visser
      • Christina Abdel Shaheed
      • Michael A Wewege
      • Benedict M Wand
      • Sylvia M Gustin
      • Neil E O'Connell
      • James H McAuley
    1 Insight on
    • High evidence
    • Clinical

    There is no clear evidence that intravenous magnesium reduces pain intensity in the immediate term (MD -2.00, 95% CI -14.43 to 10.43; 1 study, 55 participants; low certainty) and short term (MD -3.47, 95% CI -15.25 to 8.31; 2 studies, 82 participants; low certainty).

    Effect
    Neutral
    Effect size
    Small
    Significant
    No
Back to top